Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients

References

• Hahn EA, Glendenning GA, Sorensen MV, et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol 2003;21:2138–2146.
   PubMed Web of Science ®Google Scholar
• Deininger M, O’Brien SG, Guilhot F, et al. International randomized study of interferon Vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. ASH Annual Meeting Abstracts 2009;114:22.
   Google Scholar
• Kim D, Goh HG, Kim SH, et al. Comprehensive therapeutic outcomes of frontline imatinib mesylate in newly diagnosed chronic phase chronic myeloid leukemia patients in Korea: feasibility assessment of current ELN recommendation. Int J Hematol 2012;96:47–57.
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, Antolini L, Mahon FX, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 2011;103:553–561.
   PubMed Web of Science ®Google Scholar
• de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008;26:3358–3363.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kantarjian HM, Goldberg SL, et al. High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. J Clin Oncol 2009;27:4754–4759.
   PubMed Web of Science ®Google Scholar
• Cervantes F, Lopez-Garrido P, Montero MI, et al. Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group. Haematologica 2010;95:1317–1324.
   PubMed Web of Science ®Google Scholar
• Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010;11: 1029–1035.
   PubMed Web of Science ®Google Scholar
• Yhim HY, Lee NR, Song EK, et al. Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front- line imatinib mesylate therapy and achieved complete molecular response. Leuk Res 2012;36:689–693.
   PubMed Web of Science ®Google Scholar
• Takahashi N, Kyo T, Maeda Y, et al. Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica 2012;97:903–906.
   PubMed Web of Science ®Google Scholar
• Lee SE, Choi SY, Bang JH, et al. Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib. Am J Hematol 2013;88:449–454.
   PubMed Web of Science ®Google Scholar
• Branford S, Yeung DT, Ross DM, et al. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood 2013;121:3818–3824.
   PubMed Web of Science ®Google Scholar
• Richter J, Soderlund S, Lubking A, et al. Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome? J Clin Oncol 2014;32:2821–2823.
   PubMed Web of Science ®Google Scholar
• Efficace F, Baccarani M, Breccia M, et al. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood. 2011;118:4554–4560.
   PubMed Web of Science ®Google Scholar
• Phillips KM, Pinilla-Ibarz J, Sotomayor E, et al. Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison. Support Care Cancer 2013;21:1097–1103.
   PubMed Web of Science ®Google Scholar
• Aziz Z, Iqbal J, Aaqib M, et al. Assessment of quality of life with imatinib mesylate as first-line treatment in chronic phase-chronic myeloid leukemia. Leuk Lymphoma 2011;52:1017–1023.
   PubMed Web of Science ®Google Scholar
• Trask PC, Cella D, Besson N, et al. Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia. Leuk Res 2012;36:438–442.
   PubMed Web of Science ®Google Scholar
• Cella D, Jensen SE, Webster K, et al. Measuring health- related quality of life in leukemia: the Functional Assessment of Cancer Therapy—Leukemia (FACT-Leu) questionnaire. Value Health 2012;15:1051–1058.
   PubMed Web of Science ®Google Scholar
• Ware JE, Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473–483.
   PubMed Web of Science ®Google Scholar
• Apolone G, Filiberti A, Cifani S, et al. Evaluation of the EORTC QLQ-C30 questionnaire: a comparison with SF-36 Health Survey in a cohort of Italian long-survival cancer patients. Ann Oncol 1998;9: 549–557.
   PubMed Web of Science ®Google Scholar
• Buysse DJ, Reynolds CF, 3rd, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193–213.
   PubMed Web of Science ®Google Scholar
• Gao H, Lee BN, Talpaz M, et al. Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia. Leukemia 2005;19:1905–1911.
   PubMed Web of Science ®Google Scholar
• Appel S, Balabanov S, Brummendorf TH, et al. Effects of imatinib on normal hematopoiesis and immune activation. Stem Cells 2005;23:1082–1088.
   PubMed Web of Science ®Google Scholar
• Agis H, Jaeger E, Doninger B, et al. In vivo effects of imatinib mesylate on human haematopoietic progenitor cells. Eur J Clin Invest 2006;36:402–408.
   PubMed Web of Science ®Google Scholar
• Loukinova E, Ranganathan S, Kuznetsov S, et al. Platelet-derived growth factor (PDGF)-induced tyrosine phosphorylation of the low density lipoprotein receptor-related protein (LRP). Evidence for integrated co-receptor function betwenn LRP and the PDGF. J Biol Chem 2002;277:15499–15506.
   PubMed Web of Science ®Google Scholar
• Fujino T, Asaba H, Kang MJ, et al. Low-density lipoprotein receptor-related protein 5 (LRP5) is essential for normal cholesterol metabolism and glucose-induced insulin secretion. Proc Natl Acad Sci U S A 2003;100:229–234.
   PubMed Web of Science ®Google Scholar
• Boucher P, Gotthardt M, Li WP, et al. LRP: role in vascular wall integrity and protection from atherosclerosis. Science 2003;300: 329–332.
   PubMed Web of Science ®Google Scholar
• Hagerkvist R, Makeeva N, Elliman S, et al. Imatinib mesylate (Gleevec) protects against streptozotocin-induced diabetes and islet cell death in vitro. Cell Biol Int 2006;30:1013–1017.
   PubMed Web of Science ®Google Scholar
• Breccia M, Muscaritoli M, Aversa Z, et al. Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment. J Clin Oncol 2004;22: 4653–4655.
   PubMed Web of Science ®Google Scholar
• Gafter-Gvili A, Ram R, Gafter U, et al. Renal failure associated with tyrosine kinase inhibitors—case report and review of the literature. Leuk Res 2010;34:123–127.
   PubMed Web of Science ®Google Scholar
• Marcolino MS, Boersma E, Clementino NC, et al. Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients. Ann Oncol 2011;22:2073–2079.
   PubMed Web of Science ®Google Scholar